Claims for Patent: 10,406,128

Summary for Patent: 10,406,128

Title:	Treatment and diagnosis of colon cancer
Abstract:	The present invention discloses novel agents and methods for diagnosis and treatment of colon cancer. Also disclosed are related arrays, kits, and screening methods.
Inventor(s):	Tavazoie; Sohail F. (New York, NY), Loo; Jia Min (New York, NY)
Assignee:	The Rockefeller University (New York, NY)
Application Number:	16/240,123
Patent Claims:	1. A method for treating gastrointestinal cancer expressing creatine kinase brain-type (CKB) in a subject in need thereof, the method comprising contacting a cell in the subject with an effective amount of beta-guanidinopropionic acid. 2. The method of claim 1, wherein the expression of CKB in the cancer is determined by a histological examination. 3. The method of claim 1, wherein the gastrointestinal cancer is metastatic. 4. The method of claim 1, wherein the subject has previously been administered at least one prior anticancer therapy. 5. The method of claim 4, wherein the at least one prior anti-cancer therapy is surgery, radiation therapy, and/or chemotherapy. 6. The method of claim 5, wherein the at least one prior anti-cancer therapy is a chemotherapy comprising irinotecan, oxaliplatin, cetuximab, and/or avastin. 7. The method of claim 1, wherein the method further comprises administering one or more additional therapeutic agents. 8. The method of claim 7, wherein the one or more additional therapeutic agents comprises irinotecan, leucovorin, and/or 5-FU. 9. The method of claim 8, wherein the one or more additional therapeutic agents comprises irinotecan, leucovorin, and 5-fluorouracil. 10. The method of claim 1, wherein the gastrointestinal cancer is colorectal cancer, pancreatic cancer, esophageal cancer, or gastric cancer. 11. The method of claim 1, wherein the effective amount of beta-guanidinopropionic acid comprises an amount sufficient to suppress metastatic progression of the gastrointestinal cancer. 12. The method of claim 11, wherein the effective amount of beta-guanidinopropionic acid comprises an amount sufficient to suppress metastatic colonization of the gastrointestinal cancer to the liver of the subject. 13. A method for treating gastrointestinal cancer in a subject in need thereof comprising: (a) providing a subject identified to have gastrointestinal cancer expressing CKB on the basis of the expression of CKB in cancer cells of the subject; and (b) contacting a cell in the subject with an effective amount of beta-guanidinopropionic acid. 14. The method of claim 13, wherein the expression of CKB in the cancer is determined by a histological examination. 15. The method of any one of claim 13, wherein the gastrointestinal cancer is metastatic. 16. The method of any one of claim 13, wherein the subject has previously been administered at least one prior anticancer therapy. 17. The method of claim 16, wherein the at least one prior anti-cancer therapy is surgery, radiation therapy, and/or chemotherapy. 18. The method of claim 17, wherein the at least one prior anti-cancer therapy is a chemotherapy comprising irinotecan, oxaliplatin, cetuximab, and/or avastin. 19. The method of claim 13, wherein the method further comprises administering one or more additional therapeutic agents. 20. The method of claim 19, wherein the one or more additional therapeutic agents comprises irinotecan, leucovorin, and/or 5-FU. 21. The method of claim 20, wherein the one or more additional therapeutic agents comprises irinotecan, leucovorin, and 5-fluorouracil. 22. The method of claim 13, wherein the gastrointestinal cancer is colorectal cancer, pancreatic cancer, esophageal cancer, or gastric cancer. 23. The method of claim 13, wherein the effective amount of beta-guanidinopropionic acid comprises an amount sufficient to suppress metastatic progression of the gastrointestinal cancer. 24. The method of claim 23, wherein the effective amount of beta-guanidinopropionic acid comprises an amount sufficient to suppress metastatic colonization of the gastrointestinal cancer to the liver of the subject. 25. A method of treating gastrointestinal cancer in a subject, the method comprising: (a) providing a subject who has been determined to have gastrointestinal cancer expressing CKB and identified as likely to benefit from treatment with beta-guanidinopropionic acid based on the expression of CKB in the gastrointestinal cancer; and (b) contacting a cell in the subject with an effective amount of beta-guanidinopropionic acid. 26. The method of claim 25, wherein the expression of CKB in the cancer is determined by a histological examination. 27. The method of claim 25, wherein the gastrointestinal cancer is metastatic. 28. The method of claim 25, wherein the subject has previously been administered at least one prior anticancer therapy. 29. The method of claim 28, wherein the at least one prior anti-cancer therapy is surgery, radiation therapy, and/or chemotherapy. 30. The method of claim 29, wherein the at least one prior anti-cancer therapy is a chemotherapy comprising irinotecan, oxaliplatin, cetuximab, and/or avastin. 31. The method of claim 25, wherein the method further comprises administering one or more additional therapeutic agents. 32. The method of claim 31, wherein the one or more additional therapeutic agents comprises irinotecan, leucovorin, and/or 5-FU. 33. The method of claim 32, wherein the one or more additional therapeutic agents comprises irinotecan, leucovorin, and 5-fluorouracil. 34. The method of claim 25, wherein the gastrointestinal cancer is colorectal cancer, pancreatic cancer, esophageal cancer, or gastric cancer. 35. The method of claim 25, wherein the effective amount of beta-guanidinopropionic acid comprises an amount sufficient to suppress metastatic progression of the gastrointestinal cancer. 36. The method of claim 35, wherein the effective amount of beta-guanidinopropionic acid comprises an amount sufficient to suppress metastatic colonization of the gastrointestinal cancer to the liver of the subject. 37. A method for treating gastrointestinal cancer in a subject, the method comprising: (a) obtaining a tissue sample of the cancer from the subject; (b) performing a histological examination of the tissue sample and identifying expression of CKB in the tissue sample; (c) identifying the subject having the expression of CKB in the tissue sample as having an increased likelihood of benefiting from treatment with beta-guanidinopropionic acid; and (d) contacting a cell in the identified subject with an effective amount of beta-guanidinopropionic acid. 38. The method of claim 37, wherein the expression of CKB in the cancer is determined by a histological examination. 39. The method of claim 37, wherein the gastrointestinal cancer is metastatic. 40. The method of claim 37, wherein the subject has previously been administered at least one prior anticancer therapy. 41. The method of claim 40, wherein the at least one prior anti-cancer therapy is surgery, radiation therapy, and/or chemotherapy. 42. The method of claim 41, wherein the at least one prior anti-cancer therapy is a chemotherapy comprising irinotecan, oxaliplatin, cetuximab, and/or avastin. 43. The method of claim 37, wherein the method further comprises administering one or more additional therapeutic agents. 44. The method of claim 43, wherein the one or more additional therapeutic agents comprises irinotecan, leucovorin, and/or 5-FU. 45. The method of claim 44, wherein the one or more additional therapeutic agents comprises irinotecan, leucovorin, and 5-fluorouracil. 46. The method of claim 37, wherein the gastrointestinal cancer is colorectal cancer, pancreatic cancer, esophageal cancer, or gastric cancer. 47. The method of claim 37, wherein the effective amount of beta-guanidinopropionic acid comprises an amount sufficient to suppress metastatic progression of the gastrointestinal cancer. 48. The method of claim 47, wherein the effective amount of beta-guanidinopropionic acid comprises an amount sufficient to suppress metastatic colonization of the gastrointestinal cancer to the liver of the subject. 49. A method of treating a subject having gastrointestinal cancer expressing CKB, the subject who has been identified as likely to respond to treatment with beta-guanidinopropionic acid, the method comprising: (a) providing a tissue sample from the subject having gastrointestinal cancer expressing CKB; (b) performing a histological examination of the tissue sample and identifying expression of CKB in the tissue sample; (c) identifying the subject having gastrointestinal cancer expressing CKB as likely respond to treatment with beta-guanidinopropionic acid; (d) contacting a cell in the identified subject with an effective amount of beta-guanidinopropionic acid. 50. The method of claim 49, wherein the expression of CKB in the cancer is determined by a histological examination. 51. The method of claim 49, wherein the gastrointestinal cancer is metastatic. 52. The method of claim 49, wherein the subject has previously been administered at least one prior anticancer therapy. 53. The method of claim 52, wherein the at least one prior anti-cancer therapy is surgery, radiation therapy, and/or chemotherapy. 54. The method of claim 53, wherein the at least one prior anti-cancer therapy is a chemotherapy comprising irinotecan, oxaliplatin, cetuximab, and/or avastin. 55. The method of claim 49, wherein the method further comprises administering one or more additional therapeutic agents. 56. The method of claim 55, wherein the one or more additional therapeutic agents comprises irinotecan, leucovorin, and/or 5-FU. 57. The method of claim 56, wherein the one or more additional therapeutic agents comprises irinotecan, leucovorin, and 5-fluorouracil. 58. The method of claim 49, wherein the gastrointestinal cancer is colorectal cancer, pancreatic cancer, esophageal cancer, or gastric cancer. 59. The method of claim 49, wherein the effective amount of beta-guanidinopropionic acid comprises an amount sufficient to suppress metastatic progression of the gastrointestinal cancer. 60. The method of claim 59, wherein the effective amount of beta-guanidinopropionic acid comprises an amount sufficient to suppress metastatic colonization of the gastrointestinal cancer to the liver of the subject.

Details for Patent 10,406,128

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2032-10-31
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2032-10-31
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2032-10-31